| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |